Expression of WASF3 in patients with non‑small cell lung cancer: Correlation with clinicopathological features and prognosis

Wu,Jie; Wang,Guang‑Chuan; Chen,Xue‑Jun; Xue,Zhan‑Rui

doi:10.3892/ol.2014.2276

Expression of WASF3 in patients with non‑small cell lung cancer: Correlation with clinicopathological features and prognosis

Authors:
- Jie Wu
- Guang‑Chuan Wang
- Xue‑Jun Chen
- Zhan‑Rui Xue
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Liaoning Medical University, Liaoning, Jinzhou 121000, P.R. China, Department of Immunology, Liaoning Medical University, Liaoning, Jinzhou 121000, P.R. China, Department of Pathology, Liaoning Medical University, Liaoning, Jinzhou 121000, P.R. China
Published online on: June 23, 2014 https://doi.org/10.3892/ol.2014.2276
Pages: 1169-1174

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Wiskott‑Aldrich syndrome protein family member 3 (WASF3) is required for invasion and metastasis in different cancer cell types, and has been demonstrated to possess prognostic value in various types of human cancer. However, to the best of our knowledge, the expression profile of WASF3 and its correlations with the clinicopathological features of non‑small cell lung cancer (NSCLC) have not yet been described. In the present study, the mRNA expression levels of WASF3, in 38 NSCLC patients and in matched normal tissues, were assessed using quantitative polymerase chain reaction and the protein expression in 96 specimens was analyzed using immunohistochemistry. In addition, patient survival data were collected retrospectively and the association between WASF3 expression and five‑year overall survival was evaluated. The results demonstrated that the mRNA expression level of WASF3 in cancer tissues was markedly (approximately five times) higher compared with that of the normal tissues. The WASF3 protein expression profile in NSCLC was consistent with the mRNA expression result, which also correlated with the histological subtype and tumor stage. Furthermore, patients with WASF3‑positive expression were associated with a poorer prognosis compared with those exhibiting WASF3‑negative expression, and the five‑year survival rate was 20.8 and 46.5%, respectively (Kaplan‑Meier; log‑rank, P=0.004). In the multivariate analysis, which included other clinicopathological features, WASF3 emerged as an independent prognostic factor (relative risk, 0.463; 95% CI, 0.271‑0.792). These results indicate that WASF3 may be critical in the pathogenesis of NSCLC, in addition to being a valuable prognostic factor for NSCLC patients. Further investigations are required to identify the efficacy of WASF3 as a potential therapeutic target for the treatment of NSCLC.

View Figures

View References

1	Collins LG, Haines C, Perkel R and Enck RE: Lung cancer: diagnosis and management. Am Fam Physician. 75:56–63. 2007.
2	American Cancer Society. Cancer facts & figures 2012. American Cancer Society, Inc.; Atlanta: 2012
3	Ridley AJ, Schwartz MA, Burridge K, et al: Cell migration: integrating signals from front to back. Science. 302:1704–1709. 2003.
4	Pollard TD and Borisy GG: Cellular motility driven by assembly and disassembly of actin filaments. Cell. 112:453–465. 2003.
5	Sossey-Alaoui K, Ranalli TA, Li X, Bakin AV and Cowell JK: WAVE3 promotes cell motility and invasion through the regulation of MMP-1, MMP-3, and MMP-9 expression. Exp Cell Res. 308:135–145. 2005.
6	Sossey-Alaoui K, Li X and Cowell JK: c-Abl-mediated phosphorylation of WAVE3 is required for lamellipodia formation and cell migration. J Biol Chem. 282:26257–26265. 2007.
7	Sossey-Alaoui K, Downs-Kelly E, Das M, Izem L, Tubbs R and Plow EF: WAVE3, an actin remodeling protein, is regulated by the metastasis suppressor microRNA, miR-31, during the invasion-metastasis cascade. Int J Cancer. 129:1331–1343. 2011.
8	Sossey-Alaoui K, Safina A, Li X, Vaughan MM, Hicks DG, Bakin AV and Cowell JK: Down-regulation of WAVE3, a metastasis promoter gene, inhibits invasion and metastasis of breast cancer cells. Am J Pathol. 170:2112–2121. 2007.
9	Teng Y, Ren MQ, Cheney R, Sharma S and Cowell JK: Inactivation of the WASF3 gene in prostate cancer cells leads to suppression of tumorigenicity and metastases. Br J Cancer. 103:1066–1075. 2010.
10	Teng Y, Liu M and Cowell JK: Functional interrelationship between the WASF3 and KISS1 metastasis-associated genes in breast cancer cells. Int J Cancer. 129:2825–2835. 2011.
11	Chen S, Zha X, Yang L, Li B, Liye Z and Li Y: Deficiency of CD3gamma, delta, epsilon and zeta expression in T-cells from AML patients. Hematology. 16:31–36. 2011.
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
13	Berx G, Raspé E, Christofori G, Thiery JP and Sleeman JP: Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis. 24:587–597. 2007.
14	Chiang AC and Massagué J: Molecular basis of metastasis. N Engl J Med. 359:2814–2823. 2008.
15	Savagner P: Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays. 23:912–923. 2001.
16	Spaderna S, Schmalhofer O, Hlubek F, Jung A, Kirchner T and Brabletz T: Epithelial-mesenchymal and mesenchymal-epithelial transitions during cancer progression. Verh Dtsch Ges Pathol. 91:21–28. 2007.
17	Nguyen DX and Massagué J: Genetic determinants of cancer metastasis. Nat Rev Genet. 8:341–352. 2007.
18	Nguyen DX, Bos PD and Massagué J: Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 9:274–284. 2009.
19	Sossey-Alaoui K: Surfing the big WAVE: Insights into the role of WAVE3 as a driving force in cancer progression and metastasis. Semin Cell Dev Biol. 24:287–297. 2013.
20	Fernando HS, Sanders AJ, Kynaston HG and Jiang WG: WAVE3 is associated with invasiveness in prostate cancer cells. Urol Oncol. 28:320–327. 2010.
21	Kulkarni S, Augoff K, Rivera L, McCue B, Khoury T, Groman A, et al: Increased expression levels of WAVE3 are associated with the progression and metastasis of triple negative breast cancer. PLoS One. 7:e428952012.
22	Zhang Y, Guan XY, Dong B, Zhao M, Wu JH, Tian XY and Hao CY: Expression of MMP-9 and WAVE3 in colorectal cancer and its relationship to clinicopathological features. J Cancer Res Clin Oncol. 138:2035–2044. 2012.
23	Suetsugu S and Takenawa T: Regulation of cortical actin networks in cell migration. Int Rev Cytol. 229:245–286. 2003.
24	Millard TH, Sharp SJ and Machesky LM: Signalling to actin assembly via the WASP (Wiskott-Aldrich syndrome protein)-family proteins and the Arp2/3 complex. Biochem J. 380:1–17. 2004.
25	Sossey-Alaoui K, Li X, Ranalli TA and Cowell JK: WAVE3-mediated cell migration and lamellipodia formation are regulated downstream of phosphatidylinositol 3-kinase. J Biol Chem. 280:21748–21755. 2005.
26	Teng Y, Ngoka L, Mei Y, Lesoon L and Cowell JK: HSP90 and HSP70 proteins are essential for stabilization and activation of WASF3 metastasis-promoting protein. J Biol Chem. 287:10051–10059. 2012.
27	Condeelis J, Singer RH and Segall JE: The great escape: when cancer cells hijack the genes for chemotaxis and motility. Annu Rev Cell Dev Biol. 21:695–718. 2005.
28	Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 9:537–549. 2009.
29	Engel FB, Schebesta M, Duong MT, Lu G, Ren S, Madwed JB, et al: p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev. 19:1175–1187. 2005.
30	Hui L, Bakiri L, Stepniak E and Wagner EF: p38alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle. 6:2429–2433. 2007.
31	Lee RJ, Albanese C, Stenger RJ, Watanabe G, Inghirami G, Haines GK III, et al: pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells. J Biol Chem. 274:7341–7350. 1999.
32	Ricote M, García-Tuñón I, Bethencourt F, Fraile B, Onsurbe P, Paniagua R and Royuela M: The p38 transduction pathway in prostatic neoplasia. J Pathol. 208:401–407. 2006.
33	Recio JA and Merlino G: Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene. 21:1000–1008. 2002.